- The company reported a net loss of $21.8 million for fiscal 2025, compared to a loss of $44.58 million last year.
- On a per-share basis, FY25 net loss was $8.35, versus $41.89 in fiscal 2024.
- Loss from operations for the year was $23 million, narrower than the $51.8 million loss incurred in the prior year.
- Full-year R&D expenses totaled $11.5 million, compared to $26.1 million last year.
- General and administrative expenses declined to $11.48 million in 2025 from $25.6 million in FY24.
- Cellectar is preparing to submit Conditional Marketing Authorization for iopofosine I 131 to the European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia.
- It has initiated the Phase-1B dose-finding study for CLR 125 in Triple Negative Breast Cancer, with early data expected by mid-year 2026.
Earnings
Earnings Summary: Cellectar Biosciences (CLRB) FY25 net loss narrows
NYSE
$CLRB · Earnings
“Cellectar Biosciences, Inc.
ManojNair · March 4, 2026
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a biopharmaceutical company engaged in the discovery and development of cancer drugs, reported a narrower net loss for fiscal 2025.